# A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure

Source: https://onco.cc/trials/nct07854509/  
OnCo record `nct07854509` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of CR-001 run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., not yet recruiting.

## Summary

A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure is a phase 2 interventional study registered as NCT07854509 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 110 participants planned, started 2026-10-15. Conditions recorded: Non-Squamous Non-Small Cell Lung Cancer. Interventions recorded: SKB264+SKB118.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07854509
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate Sacituzumab Tirumotecan (SKB264) in Combination With SKB118 for the Treatment of EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer in Participants Who Have Failed Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Therapy
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT07854509: https://clinicaltrials.gov/study/NCT07854509

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [CR-001](https://onco.cc/drugs/cr-001/)
- companies: [Crescent Biopharma](https://onco.cc/companies/crescent-biopharma/), [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07854509.json